Kathmandu— Moderna and Merck have announced promising results from a late-stage clinical trial of an individualized mRNA cancer vaccine, Intismeran, which significantly reduced the risk of melanoma recurrence and tumor spread. The treatment combines mRNA technology with immunotherapy drug Keytruda to train patients’ immune systems to target specific mutations in cancer cells. These interim findings represent the first positive late-stage trial result for an mRNA cancer vaccine and have already prompted discussions with regulatory bodies regarding potential approval, potentially benefiting thousands of high-risk melanoma patients as early as next year.

Trial Results and Potential Impact

The clinical trial met its primary goals of reducing both cancer recurrence and the spread of tumors. While detailed results are still pending publication at an upcoming medical meeting, the initial findings spurred a significant surge in Moderna’s stock price. According to Moderna President Stephen Hoge, this vaccine could offer a new treatment option for the over 1.5 million people living with melanoma in the United States as of 2023.

How the Vaccine Works

Intismeran is designed to personalize cancer treatment by training the patient’s immune system to recognize and attack tumor cells based on their unique genetic mutations. This approach, tested alongside Merck's Keytruda immunotherapy drug, represents a significant advancement in cancer treatment strategies. Similar mRNA-based approaches are currently being investigated for other types of cancers, including lung, breast, and pancreatic cancers.

A Turning Point for Immunotherapy

Experts believe these results could mark the beginning of a new era in solid tumor cancer treatment. Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, described the positive trial outcome as ushering in “truly this next phase in immunotherapy,” adding that, “This is an auspicious start – this is where things begin.” The development builds on previous research suggesting mRNA vaccines could effectively stimulate immune responses against cancer cells.

Historical Context of mRNA Research

The success of Intismeran comes after a period when funding for mRNA research faced cuts. Despite these challenges, the technology has now demonstrated its potential not only in combating infectious diseases like COVID-19 but also in tackling complex conditions such as cancer.

Merck and Moderna are currently engaging with regulators to discuss the possibility of bringing Intismeran to market, potentially offering a new treatment option for melanoma patients within the next year.

(With inputs from Al Jazeera)

Originally published on abcnews.com.np.